Buy & Sell Las Vegas Sands Corp. (LVS) – Las Vegas Sands Corp. Price Today
Aura AI Summary
Key Stats
- $33.90BMarket Cap
- Consumer CyclicalSector
- -13.48%3M Drawdown
- $46.29BEnterprise Value
- 2.15%Dividend Yield
- 68 daysTypical Hold Time
Las Vegas Sands Corp. (LVS) is currently valued at a market capitalization of $33.90B, with an enterprise value of $46.29B. Over the past 52 weeks, Las Vegas Sands Corp. has traded between a low of $39.8 and a high of $69.49, highlighting its annual price range. Over the past three months, Las Vegas Sands Corp. has recorded a drawdown of -13.48%, reflecting recent price volatility. Las Vegas Sands Corp. offers a dividend yield of 2.15%, with the most recent dividend of $0.30 paid on 05 May 26. On average, investors hold Las Vegas Sands Corp. for approximately 68 days, indicating typical investor behavior on the platform.
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Most Recent News
Hedge funds boost semiconductor bets as SOXX ETF exposure hits record highs in Q1 2026
In the first quarter of 2026, hedge funds dramatically increased their investments in semiconductor stocks, pushing sector exposure to a record 19% of global hedge fund portfolios, more than doubling since the start of the year. Major investors like ...

Onconetix shares jump 23.65% after clinical study boosts confidence in prostate cancer test Proclarix.
Onconetix Inc. stock surged 23.65% in after-hours trading following positive clinical validation of its prostate cancer blood test, Proclarix. Two new peer-reviewed studies from Denmark showed Proclarix can reduce unnecessary biopsies and overdiagnos...

Utilities ETF up 1.65% in quarter, driven by data center growth and renewables partnerships.
The Virtus Reaves Utilities ETF rose 1.65% in the quarter but lagged the S&P 500 Utilities Index, while delivering a 25.49% return over the past year. Key utilities like Entergy and Meta expanded their power generation commitments by 5 gigawatts to s...
